The Washington Post·2 min read·medium
FDA raised conflict of interest concerns ahead of new peptide panel - The Washington Post
R
Rachel Roubein
✦AI Summary
FDA officials raised concerns regarding potential conflicts of interest during the formation of a panel tasked with reviewing controversial peptides. The concerns centered on the appointment of individuals with ties to peptide-related businesses.
As the Trump administration was assembling a key panel to review a slate of controversial peptides, FDA officials expressed concerns about appointing those who worked for peptide-related businesses a…
politicshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in